Myomo (NYSEAMERICAN:MYO) Director Milton Mayo Morris Sells 15,000 Shares

Myomo, Inc. (NYSEAMERICAN:MYO) Director Milton Mayo Morris sold 15,000 shares of the business’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $1.41, for a total value of $21,150.00. Following the transaction, the director owned 208,391 shares in the company, valued at approximately $293,831.31. This represents a 6.71% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Myomo Price Performance

Shares of MYO stock opened at $1.44 on Friday. The company has a debt-to-equity ratio of 1.98, a quick ratio of 2.01 and a current ratio of 2.31. Myomo, Inc. has a fifty-two week low of $0.60 and a fifty-two week high of $1.89. The firm has a market cap of $57.04 million, a P/E ratio of -4.24 and a beta of 1.50. The business’s 50 day moving average price is $1.26 and its 200-day moving average price is $1.02.

Myomo (NYSEAMERICAN:MYO) last announced its earnings results on Wednesday, August 5th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01. The company had revenue of $11.70 million during the quarter, compared to the consensus estimate of $10.35 million. Myomo had a negative return on equity of 138.85% and a negative net margin of 33.53%. On average, equities research analysts anticipate that Myomo, Inc. will post -0.32 earnings per share for the current year.

Institutional Trading of Myomo

Institutional investors and hedge funds have recently modified their holdings of the business. Cubist Systematic Strategies LLC boosted its holdings in shares of Myomo by 157.4% during the 1st quarter. Cubist Systematic Strategies LLC now owns 49,101 shares of the company’s stock valued at $236,000 after acquiring an additional 30,028 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in shares of Myomo during the first quarter valued at approximately $75,000. Jane Street Group LLC lifted its position in Myomo by 84.2% during the first quarter. Jane Street Group LLC now owns 162,658 shares of the company’s stock valued at $782,000 after purchasing an additional 74,338 shares during the period. Acadian Asset Management LLC purchased a new stake in Myomo in the first quarter worth approximately $114,000. Finally, Geode Capital Management LLC boosted its holdings in Myomo by 160.8% in the second quarter. Geode Capital Management LLC now owns 669,281 shares of the company’s stock worth $1,446,000 after purchasing an additional 412,631 shares during the last quarter. Institutional investors own 44.99% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Ascendiant Capital Markets increased their price target on shares of Myomo from $9.50 to $10.00 and gave the stock a “buy” rating in a research note on Monday, June 8th. Two analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $10.00.

Myomo Company Profile

Myomo, Inc (NYSE American: MYO) is a medical robotics company specializing in developing and commercializing powered orthotic devices designed to restore mobility and function for individuals with upper-limb weakness. The company’s flagship product, the MyoPro®, is an FDA-cleared, wearable robotic orthosis that leverages proprietary sensors and actuators to detect and amplify users’ own muscle signals, enabling patients with conditions such as stroke, spinal cord injury, muscular dystrophy and other neuromuscular disorders to perform daily activities with greater independence.

Myomo markets the MyoPro through a network of licensed orthotic and prosthetic professionals, clinics and hospitals across North America.